Related Experiment Video
Updated: May 30, 2026
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
Effectiveness of intraperitoneal hyperthermo-chemotherapy for malignant peritoneal mesothelioma and estimation of its
Satoru Yamaguchi1, Takayuki Asao, Soichi Tsutsumi
1Department of General Surgical Science, Gunma University Graduate School, Graduate School of Medicine, Gunma, Japan. syamaguc@med.gunma-u.ac.jp
Abstract:
Malignant peritoneal mesothelioma is a rare neoplasm derived from the peritoneum of the abdominal cavity. Here, we report on a case of malignant peritoneal mesothelioma that expanded aggressively after initial surgery, followed by successful treatment with cytoreductive surgery, intra-abdominal hyperthermo-chemotherapy, to allow the patient to perform daily activities with reduced symptoms. The therapeutic effects were monitored by FDG-PET/CT. The patient, a 55-year-old female, was referred to our hospital with a diagnosis of pelvic tumor. Laparotomy and cytoreductive surgery revealed the diagnosis of malignant mesothelioma. The tumor progressed rapidly in the abdominal cavity, so cytoreduction and intra-abdominal hyperthermo-chemotherapy were performed as strong local therapies. In addition, monthly hyperthermo-chemotherapy was performed. The patient lived for 21 months after the first surgery. Severe bowel obstruction and malignant ascites did not appear. Cancerous pain was controllable throughout this portion of her life. In conclusion, we experienced a case of malignant peritoneal mesothelioma and treated it with hyperthermo-chemotherapy. This treatment helped the patient to maintain daily activities throughout the remainder of her life. Thus, hyperthermo-chemotherapy can be considered an option in the treatment of malignant peritoneal mesothelioma.
Insights
Malignant peritoneal mesothelioma, a rare cancer, was successfully treated with cytoreductive surgery and intra-abdominal hyperthermo-chemotherapy. This approach helped a patient maintain daily activities with reduced symptoms for 21 months.
Area of Science:
- Oncology
- Surgical Oncology
Background:
- Malignant peritoneal mesothelioma is a rare abdominal neoplasm.
- Aggressive tumor expansion post-initial surgery presents a treatment challenge.
Observation:
- A 55-year-old female presented with a pelvic tumor, diagnosed as malignant mesothelioma.
- The tumor showed rapid progression after initial cytoreductive surgery.
Findings:
- Combined cytoreductive surgery and intra-abdominal hyperthermo-chemotherapy (IAHT) led to symptom reduction and maintained daily activities.
- The patient survived for 21 months post-surgery without severe complications like bowel obstruction or malignant ascites.
- FDG-PET/CT monitoring confirmed therapeutic effects.
Implications:
- Intra-abdominal hyperthermo-chemotherapy is a viable treatment option for malignant peritoneal mesothelioma.
- This multimodal approach can improve quality of life for patients with this rare cancer.
- Further research into IAHT for malignant peritoneal mesothelioma is warranted.
